Boston Scientific (BSX: sentiment, chart, options) shares are about 1.5% higher after the firm said it plans to sell its Santa Rosa Corp. unit to TV2 Holding Company for $30 million in cash. The terms of the deal include a warrant for Boston Scientific to purchase a minority interest in privately held TV2. In a statement, BSX said the sale is "helping realign our cost structure and simplify our operating model as we progress toward achieving our overall goals of restoring profitable growth, increasing shareholder value and strengthening Boston Scientific for the future."

In other BSX news hitting the Street today, the company's Spirit II trial results, comparing the safety and efficiancy of 2 coronary stents, back up the strength of the treatments. The firm's Xience V Promus Everolimus-Eluting Coronary Stent will be made immediately available to the public pending approval from the Food & Drug Administration, which Boston Scientific expects sometime in the first half of this year.

Technically, BSX continues to edge sideways between the 12 and 13 levels. This narrow range has confined the equity's movements since February. As a result of the shares' lackluster price action, option traders are displaying a pessimistic bias. The Schaeffer's put/call open interest ratio of 0.79 is just 12 percentage points away from a bearish peak.

In today's trading, the most active short-term option is the May 12.50 call. So far, this narrowly in-the-money call has traded volume of 2,500 contracts on open interest of 22,922.